GlassScriptPhysician profile
Kellie A Gardner
NPI 1841634847
$1,446.16
in general payments reported to CMS, 2019-2025
20 companies · $1,085 in 2025
The $1,085 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $94.06 · 2024: $267 · 2025: $1,085.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,446.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $285.49 | 2023-2025 | Tecentriq, Alecensa, Itovebi |
| Caris Mpi, INC. | $190.97 | 2025 | Mi Cancer Seek |
| E.R. Squibb & Sons, L.L.C. | $151.79 | 2025 | Opdivo |
| Jazz Pharmaceuticals INC. | $143.12 | 2024 | |
| Novartis Pharmaceuticals Corporation | $110.46 | 2024-2025 | |
| Beone Medicines USA, INC. | $85.47 | 2025 | Tevimbra, Brukinsa |
| Merck Sharp & Dohme LLC | $74.20 | 2024-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $64.70 | 2024-2025 | Enhertu |
| Abbvie INC. | $63.32 | 2025 | |
| Janssen Biotech, INC. | $41.60 | 2025 | Rybrevant, Talvey, Tecvayli |
| Exelixis INC. | $34.38 | 2025 | Cabometyx |
| Genmab U.S., INC. | $30.69 | 2025 | Epkinly |
| Glaxosmithkline, LLC. | $28.10 | 2025 | Blenrep |
| Regeneron Healthcare Solutions, INC. | $25.20 | 2025 | Libtayo |
| Iovance Biotherapeutics, INC. | $23.84 | 2025 | Amtagvi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $21.38 | 2025 | Zynyz |
| Lilly USA, LLC | $20.26 | 2025 | Verzenio, Jaypirca |
| Accord Healthcare, INC. | $18.81 | 2025 | |
| Novocure INC. | $17.40 | 2024 | Optune Lua (Novottf-200t) |
| Puma Biotechnology, INC. | $14.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.